ZZZhiyuan Zhang

Zhiyuan Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhiyuan Zhang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Jianmin Xu

    Wentao Tang, MD, PhD and Jianmin Xu, MD, PhD, Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China

    6 shared publications
  • Qingyang Feng

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    5 shared publications
  • Guodong He

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    4 shared publications
  • Peng Zheng

    Fudan Univ, Zhongshan Hosp, Dept Gen Surg, 180 Fenglin Rd, Shanghai, Peoples R China

    4 shared publications
  • Yang Lv

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    4 shared publications
  • Yihao Mao

    Fudan Univ, Zhongshan Hosp, Dept Gen Surg, 180 Fenglin Rd, Shanghai, Peoples R China

    4 shared publications

Latest Publications

  • Open Access

    RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer

    by Kun Wang, Yajie Chen, Zhiyuan Zhang, Ruiyan Wu, Menglong Zhou, Wang Yang, Juefeng Wan, Lijun Shen, Hui Zhang, Yan Wang, et al.

    Currently, the prognosis for metastatic colorectal cancer (mCRC) still remains poor. The management of mCRC has become manifold because of the varied advances in the systemic and topical treatment approaches. For patients with limited number of metastases, radical local therapy plus systemic therapy can be a good choice to achieve long-term tumor control. In this study, we aimed to explore the efficacy and safety of the combination of fruquintinib, tislelizumab, and stereotactic ablative radiotherapy (SABR) in mCRC (RIFLE study). RIFLE was designed as a single-center, single-arm, prospective Phase II clinical trial. A total of 68 mCRC patients who have failed the first-line standard treatment will be recruited in the safety run-in phase (n = 6) and the expansion phase (n = 62), respectively. Eligible patients will receive SABR followed by fruquintinib (5 mg, d1–14, once every day) and tislelizumab (200 mg, d1, once every 3 weeks) within 2 weeks from completion of radiation. The expansion phase starts when the safety of the treatment is determined (dose limiting toxicity occur in no more than one-sixth of patients in the run-in phase). The primary end point is the objective response rate. The secondary end points include the disease control rate, duration of response, 3-year progression-free survival rate, 3-year overall survival rate, and toxicity. The results of this trial will provide a novel insight into SABR in combination with PD-1 antibody and vascular endothelial growth factor receptor inhibitor in the systematic treatment of metastatic colorectal cancer, which is expected to provide new therapeutic strategies and improve the prognosis for mCRC patients. NCT04948034 (ClinicalTrials.gov).


  • Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer

    by Lv Yang, Tang WenTao, Zhang ZhiYuan, Lin Qi, Luo YuXiang, Zheng Peng, Li Ke, Jia XiaoNa, Pang YuZhi, Ji MeiLing, et al.

    Colorectal cancer (CRC) is the leading cause of cancer associated death worldwide. Ferroptosis is a newly defined form of regulated cell death characterized by the accumulation of lipid hydroperoxides and exerts an increased attention for cancer treatment. However, little is known about ferroptosis in CRC. In this study, through whole genome sequencing and external differential differentiated expression analysis, we identify CUL9 as a novel important modulator for ferroptosis in CRC. Here we demonstrated that CUL9 can binds p53 to ubiquitylate heterogeneous nuclear ribonucleoprotein C for degradation. Overexpression of CUL9 increases resistance to erastin-induced ferroptosis. Then, we discovered this resistance was mediated by CUL9-HNRNPC-MATE1 negative loop, which can provide us with a novel target to overcome drug resistance to ferroptosis activators. Finally, we found that targeting MDM2 was developed as an effective strategy to destroy precious drug-resistant CRC cells.


  • Open Access

    HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer

    by Zhiyuan Zhang, Guodong He, Yang Lv, Yu Liu, Zhengchuan Niu, Qingyang Feng, Ronggui Hu, Jianmin Xu

    E3 ligase is widely reported to exert fundamental functions in cancers. Through rigorous bioinformatic analysis concentrating E3 ligases based on data from Genotype-Tissue Expression (GTEx) and data from The Cancer Genome Atlas (TCGA), HERC3 was indicated to be downregulated in colorectal cancer (CRC) and HERC3 downregulation showed poor overall survival (OS) and disease-free survival (DFS). Through qRT-PCR, western blotting and Immunohistochemistry (IHC), analytical results were validated based on tissues in Zhongshan hospital. Functionally, HERC3 was indicated to inhibit the migration, invasion and metastasis in vitro and in vivo through transwell assays, wound healing assays and vivo experiments. And HERC3 could regulate epithelial-mesenchymal transition (EMT) in CRC. Furthermore, immunoprecipitation (IP), coimmunoprecipitation (co-IP) and GST-pulldown assays indicated that HERC3 could directly interact with EIF5A2 in vitro and in vivo through the RCC1 domain in HERC3. And HERC3 could function as an E3 to promote the K27 and K48-linked ubiquitination degradation of EIF5A2 via the HECT domain in HERC3, besides, K47, K67, K85, and K121 in EIF5A2 were identified as ubiquitination sites. In addition, HERC3 was indicated to affect the migration, invasion and metastasis and further regulatE EMT via EIF5A2/TGF-/Smad2/3 signal. The present study may provide insight into the mechanism of EMT in CRC.


  • Open Access

    Significance of Surgery in the Treatment of Colorectal Cancer Ovarian Metastases: A Retrospective Case Matching Study

    by Yuqiu Xu, Qingyang Feng, Yijiao Chen, Yihao Mao, Zhiyuan Zhang, Yang Lv, Peng Zheng, Shanchao Yu, Guodong He, Jianmin Xu

    Purpose: Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Ovarian metastases (OM), which are low in frequency, are reported to occur in 3– 14% of women with CRC and have a poor prognosis. Studies have shown that surgical treatment may benefit patients with ovarian metastases arising from CRC. However, the precise benefit of surgery is uncertain. This study was implemented to identify treatment outcomes associated with ovarian metastases from CRC, as well as to clarify the importance of primary and metastatic lesion resection. Patients and Methods: Between January 2008 and December 2018, the medical records of 93 patients diagnosed with CRC ovarian metastases (CRC-OM) at Zhongshan Hospital, Fudan University, Shanghai, were retrospectively analyzed. Clinicopathological characteristics as well as prognostic conditions were evaluated. Nineteen patients with only synchronous OM and 38 patients without metastases were matched to compare surgical outcomes. Results: The median overall survival (OS) of the total 93 CRC-OM patients was 26 months. The median OS times of patients with ovary-only metastases (n=37) and those with other metastases (n=56) were 49 months and 20 months, respectively. Patients with only ovarian metastases had a longer OS time (p< 0.001) than patients with other metastases. Patients with ovarian metastases resected (n=76) (p< 0.001) had a longer OS time than those unresected (n=17). Synchronous (n=54) and metachronous (n=39) metastases indicated no significant survival difference. Patients with only ovarian metastases could achieve similar OS times to those of patients without metastases after primary and metastasis surgery. Conclusion: Surgical treatment is very important for CRC-OM patients. Primary and metastatic lesion resection can help achieve longer survival times.


  • Open Access

    Analysis of relapse-associated alternative mRNA splicing and construction of a prognostic signature predicting relapse in I–III colon cancer

    by Zhiyuan Zhang, Qingyang Feng, Caiwei Jia, Peng Zheng, Yang Lv, Yihao Mao, Yuqiu Xu, Guodong He, Jianmin Xu


  • Open Access

    Analysis of tumor microenvironment‐related key mRNAs and construction of a prognosis signature in colon cancer

    by Zhiyuan Zhang, Guodong He, Qingyang Feng, Peng Zheng, Yang Lv, Yihao Mao, Yuqiu Xu, Jianmin Xu


  • Open Access

    Analysis of relapse-associated alternative mRNA splicing and construction of a prognostic signature predicting relapse in I–III colon cancer

    by Zhiyuan Zhang, Qingyang Feng, Peng Zheng, Yang Lv, Yihao Mao, Yuqiu Xu, Guodong He, Jianmin Xu

    Background : The literature depicting the effects of alternative splicing (AS) events on relapse of colon cancer is little and there is no signature based on the alternative splicing. Methods : The bioinformatic analysis was performed based on data of The Cancer Genome Atlas (TCGA) to identify the relapse-associated ASs, the potential interactions were further analyzed and a robust signature was built after univariate Cox regression, LASSO Cox regression, and multivariate Cox regression analysis to predict the relapse in I–III colon cancer. Molecular subtypes was identified based on the signature. Results : We identified 1912 ASs of 1384 mRNA, based on the relapse-associated ASs, we constructed the network of protein-protein interactions (PPI) and ASs-splicing factors (SF) interactions. 1294 of proteins with 7396 interactions were included in the PPI network. 14 SFs combined with 78 relapse-associated ASs were included in the AS-SF network. We finally built a robust signature to predict the relapse of I–III colon cancer with a considerable AUC value in both the training group and the test group (0.857,0.839). Based on the ASs involved in the signature, samples were classified into 4 molecular subgroups distinguishing the relapse rate in diverse groups. Conclusion : Our study provides a profile of relapse-associated ASs in I–III colon cancer and build a robust signature to predict the relapse of I–III colon cancer patients and further classify the patients into 4 molecular subtypes.


  • Upregulated miR‐1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC

    by Zhiyuan Zhang, Jie Li, Yuanjian Huang, Wen Peng, Wenwei Qian, Jiou Gu, Qingyuan Wang, Tao Hu, Dongjian Ji, Bing Ji, et al.

    Objectives: Micro RNA s (mi RNA s) as small noncoding RNA molecules function by regulating their target genes negatively. MiR‐1258 was widely researched in multicancers, but its role remains unclear in colorectal cancer ( CRC ). Methods: The expression of miR‐1258 and its specific target gene were detected in human CRC specimens and cell lines by mi RNA RT ‐ PCR , qRT ‐ PCR and Western blot. The effects of miR‐1258 on CRC proliferation were evaluated using CCK ‐8 assays, EdU incorporation, colony formation assays and cell‐cycle assays; in vitro and the in vivo effects were investigated using a mouse tumorigenicity model. Luciferase reporter and RIP assays were employed to identify interactions between miR‐1258 and its specific target gene. Results: MiR‐1258 was downregulated in CRC tissues and CRC cell lines, and upregulated miR‐1258 was proved to inhibit proliferation and arrest cell cycle at G0/G1 in vitro and vivo. Luciferase reporter, RIP and western blot assays revealed E2F8 to be a direct target of miR‐1258. The effects of miR‐1258 in proliferation and cell cycle regulation can be abolished by E2F8 through rescue experiments. By directly targeting E2F8, miR‐1258 influenced the expression of several cell‐cycle factors, including cyclin D1 ( CCND 1) and cyclin dependent kinase inhibitor 1A (p21). Conclusion: MiR‐1258 may function as a suppressive factor by negatively controlling E2F8, thus, highlighting the potential role of miR‐1258 as a therapeutic target for human CRC .


  • Open Access

    Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer

    by Sen Wang, Zhiyuan Zhang, Wenwei Qian, Dongjian Ji, Qingyuan Wang, Bing Ji, Yue Zhang, Chuan Zhang, Ye Sun, Chunyan Zhu, et al.

    Introduction: Vasculogenic mimicry (VM) describes the formation of an epithelial-independent tumor microcirculation system that differs from traditional angiogenesis. Angiogenesis and the formation of VM are closely related through the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway and the epithelial–mesenchymal transition (EMT) process. Materials and methods: In this study, 8-Br-cAMP, a cAMP analog and PKA activator, was used to activate the cAMP/PKA pathway to evaluate the effects of cAMP/PKA on angiogenesis and VM in colorectal cancer (CRC) cells. We used a syngeneic model of CRC in BALB/c mice. Results: We discovered that treatment with 8-Br-cAMP significantly reduced tumor number compared to control mice after the 7th, 14th, and 28th days of treatment. VM was evaluated by periodic acid–schiff (PAS)–CD31 staining, and we found that VM was inhibited by 8-Br-cAMP treatment in vivo. Immunohistochemistry confirmed the inhibition of vascular endothelial growth factor (VEGF) and cAMP and the activation of PKA by 8-Br-cAMP; quantitative real-time-PCR (qRT-PCR) demonstrated that 8-Br-cAMP regulated the expression of vascular endothelial (VE)-cadherin, matrix metalloproteinase 2 (MMP2), ephrin type-A receptor 2 (EphA2), and VEGF in vivo. Experiments in vitro revealed that treatment with 8-Br-cAMP and U0126 decreased VEGF expression through PKA–ERK in CT26 cells by qRT-PCR. We further confirmed that tube formation of human umbilical vein endothelial cells was inhibited by 8-Br-cAMP in vitro. Discussion: This study demonstrates that angiogenesis and VM are inhibited by 8-Br-cAMP treatment. Our data indicate that 8-Br-cAMP acts through the cAMP/PKA–ERK pathway and through EMT processes in CRC. These findings provide an insight into mechanisms of CRC and suggest that the cAMP/PKA–ERK pathway is a novel potential therapeutic target for the treatment of CRC.


  • Open Access

    Construction of a ceRNA network reveals potential lncRNA biomarkers in rectal adenocarcinoma

    by Zhiyuan Zhang, Sen Wang, Dongjian Ji, Wenwei Qian, Qingyuan Wang, Jie Li, Jiou Gu, Wen Peng, Tao Hu, Bing Ji, et al.

    Competing endogenous RNAs (ceRNAs) render the functions of long non‑coding RNAs (lncRNAs) more complicated during cancer processes. Potential lncRNA biomarkers and their roles as ceRNAs have not been clearly described for rectal adenocarcinoma (READ). In the present study, we extracted data from The Cancer Genome Atlas (TCGA) including data from 167 tumor samples and 10 adjacent non‑tumor samples. A total of 202 lncRNAs, 190 microRNAs (miRNAs) and 1,530 mRNAs were identified as READ‑specific RNAs [log2(fold‑change)>2, FDR<0.01]. The Gene Ontology (GO) biological processes and the Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways were analysed for 1,530 specific mRNAs. Among 202 READ‑specific lncRNAs, 7 lncRNAs were identified as being associated with overall survival of READ patients. Then, a ceRNA network was constructed with 34 key lncRNAs, 25 miRNAs and 65 mRNAs. A total of 7 lncRNAs from the network were revealed to be linked to clinical features. The results of qRT‑PCR ascertained that our analysis was credible. Overall, this research provides a novel perspective from which to study the lncRNA‑related ceRNA network in READ and assists in the identification of new potential biomarkers to be used for diagnostic and prognostic purposes.